Ja Sung Choi, MD, PhD1, Sung-Whan Kim, PhD2
1Catholic Kwandong University, Incheon, Inch'on-jikhalsi, Republic of Korea; 2Incheon, Inch'on-jikhalsi, Republic of Korea
Introduction: Although human adipose tissue-derived stromal vascular fraction (SVF) has been considered a promising source of stem cells, its characteristics relevant to treatment of a damaged liver have not been fully elucidated. In the present study, we sought to characterize the hepatogenic and anti-fibrogenic property of human SVF and determine the therapeutic utility of SVF in the liver cirrhosis model.
Methods: We performed microarray, quantitative (q)-PCR experiments, and in vivo therapeutic assays using a liver cirrhotic mouse model.
Results: q-PCR results revealed that the well-known hepatogenic or anti-inflammatory factors hepatocyte growth factor (HGF), vascular endothelial growth factor (VEGF)-A, Interleukin (IL)-10 and microRNA(miR)-146 were more highly upregulated in SVF than in
human adipose-derived mesenchymal stem cells (ASCs). The SVF culture medium (CM) inhibited the activation of hepatic stellate cells in vitro. Injection of SVF significantly suppressed TAA-induced liver fibrosis and repaired liver function by inhibition of infiltrating inflammatory cells and induction of capillary/hepatocyte regeneration in vivo.
Discussion: Our data indicate that SVF has a high therapeutic potential for treating fibrotic liver diseases through their hepatogenic and anti-fibrogenic properties. Therefore, SVF might be a novel therapeutic alternative for the treatment of liver cirrhosis in clinical settings.
Citation: Ja Sung Choi, MD, PhD; Sung-Whan Kim, PhD. P2481 - TRANSPLANTATION OF HUMAN ADIPOSE TISSUE DERIVED-SVF ENHANCE LIVER FUNCTION IN FIBROTIC LIVER THROUGH HIGH HEPATOGENIC AND ANTI-FIBROTIC CAPABILITIES. Program No. P2481. ACG 2019 Annual Scientific Meeting Abstracts. San Antonio, Texas: American College of Gastroenterology.